What pathophysiological and mechanistic factors associated with the GLP-1 agonist liraglutide might explain the reduction in overall mortality, MACE, and CV mortality reported in the LEADER trial?

What pathophysiological and mechanistic factors associated with the GLP-1 agonist liraglutide might explain the reduction in overall mortality, MACE, and CV mortality reported in the LEADER trial?

What pathophysiological and mechanistic factors associated with the GLP-1 agonist liraglutide might explain the reduction in overall mortality, MACE, and CV mortality reported in the LEADER trial?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Ralph DeFronzo, MD

Ralph DeFronzo, MD

Professor of Medicine
Chief of the Diabetes Division
The University of Texas Health Science Center at San Antonio
San Antonio, Texas